This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
By This Author:
Page 2 of 147

A Safer Way to Play the Drug Sector

By Robert Steyer

Contract research organizations aren't without risks of course, but they do offer some protection against the vagaries of the industry.

06:16AM 02/26/08

Schering-Plough's Adjusted Profits Top Estimates

By Robert Steyer

Shares rise 5.4% on the news.

02:56PM 02/12/08

Reasons to Believe in Schering-Plough

By Robert Steyer

Despite the Vytorin setback, the focus here should be on drugs in development, not products in the market.

02:05PM 02/11/08

Big Pharma Moving More Work Offshore

By Robert Steyer

Merck, Pfizer and others are getting used to a new world that requires cost discipline.

02:06PM 01/25/08

Are IPOs Poised for Another Banner Year?

By Robert Steyer

If a recession can be avoided, 2008, like last year, could be active for initial issues.

11:07AM 01/21/08

Big Pharma Considers Kicking the OTC Habit

By Robert Steyer

Several firms are debating whether to bulk up or shed lower-margin units.

06:14AM 12/18/07

Your Guide to Collecting Argillite Carvings

By Robert Steyer

Here's what you need to know about buying these rare, tradition-rich pieces from the Canadian islands.

01:40PM 12/12/07

No Easy Fix for Pfizer

By Robert Steyer

It can be done, but it will probably require some tough choices.

02:14PM 11/29/07

Is Mylan Cheap Yet?

By Robert Steyer

Shares have dropped more than 30% since May, but questions remain about its model.

03:14PM 11/28/07

Cephalon Still a Stressor

By Robert Steyer

Will that change when earnings arrive Thursday?

04:04PM 11/06/07

Page 2 of 147

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 18,010.68 -115.44 -0.64%
S&P 500 2,107.39 -13.40 -0.63%
NASDAQ 5,070.0260 -27.95 -0.55%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs